The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells

Lepletier, Ailin, Lutzky, Viviana P, Mittal, Deepak, Stannard, Kimberley, Watkins, Thomas S, Ratnatunga, Champa N, Smith, Corey, McGuire, Helen M, Kemp, Roslyn A, Mukhopadhyay, Pamela, Waddell, Nicola, Smyth, Mark J, Dougall, William C and Miles, John 2019. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. Immunology and Cell Biology 97 (2) , pp. 152-164. 10.1111/imcb.12205

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

CD96 has recently been shown to be a potent immune checkpoint molecule in mice, but a similar role in humans is not known. In this study, we provide a detailed map of CD96 expression across human lymphocyte lineages, the kinetics of CD96 regulation on T-cell activation and co-expression with other conventional and emerging immune checkpoint molecules. We show that CD96 is predominantly expressed by T cells and has a unique lymphocyte expression profile. CD96 high T cells exhibited distinct effector functions on activation. Of note, CD96 expression was highly correlated with T-cell markers in primary and metastatic human tumors and was elevated on antigen- experienced T cells and tumor-infiltrating lymphocytes. Collectively, these data demonstrate that CD96 may be a promising immune checkpoint to enhance T-cell function against human cancer and infectious disease

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Nature Publishing Group
ISSN:	0818-9641
Date of First Compliant Deposit:	17 June 2019
Date of Acceptance:	13 September 2018
Last Modified:	20 Nov 2024 20:15
URI:	https://orca.cardiff.ac.uk/id/eprint/117667

Citation Data

Cited 20 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item